Drug Interaction Potential As a Result of Cytokine Release Syndrome Using a Physiologically Based Pharmacokinetic Model: Case Study of Teclistamab

Marie‐Emilie Willemin(Janssen (Belgium)), Suzette Girgis(Centre Hospitalier Universitaire de Nantes), Shun Xin Wang Lin(Centre Hospitalier Universitaire de Nantes), Rachel Kobos(Centre Hospitalier Universitaire de Nantes), Raluca Verona(Centre Hospitalier Universitaire de Nantes), Arnob Banerjee(Johnson & Johnson (United States)), Baolian Liu(Janssen (United States)), Ming Qi(University of Cape Town), Xin Miao(Johnson & Johnson (United States)), Loeckie De Zwart(Janssen (Belgium)), Liviawati S. Wu(Janssen (United States)), Danièle Ouellet(Janssen (United States))
Blood
November 15, 2022
10.1182/blood-2022-162856
Cited by 2

Related Papers

Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study
|The Lancet|2021|1.7k
Teclistamab in Relapsed or Refractory Multiple Myeloma
|New England Journal of Medicine|2022|1.2k
Asymmetric T Lymphocyte Division in the Initiation of Adaptive Immune Responses
|Science|2007|852
Ciltacabtagene Autoleucel, an Anti–B-cell Maturation Antigen Chimeric Antigen Receptor T-Cell Therapy, for Relapsed/Refractory Multiple Myeloma: CARTITUDE-1 2-Year Follow-Up
|Journal of Clinical Oncology|2022|647
Application of a 5-tiered scheme for standardized classification of 2,360 unique mismatch repair gene variants in the InSiGHT locus-specific database
|Nature Genetics|2013|476